Log In Sign up
The largest database of trusted experimental protocols

Human stem cell factor

Manufactured by R&D Systems
Visit Supplier
Sourced in Japan, China, United States

Human stem cell factor is a recombinant protein that acts as a growth and differentiation factor for hematopoietic stem and progenitor cells. It promotes the survival, proliferation, and differentiation of these cell types. The protein is produced in a mammalian cell expression system.

Automatically generated - may contain errors

Lab products found in correlation

Penicillin streptomycin, by Thermo Fisher Scientific (6 mentions) Dexamethasone (dex), by Merck Group (3 mentions) Human il 6, by R&D Systems (2 mentions) Lymphoprep reagent, by STEMCELL (2 mentions) Human il 3, by R&D Systems (2 mentions) Penicillin, by BBI Lifesciences (2 mentions) Streptomycin, by BBI Lifesciences (2 mentions) Stem cell factor (scf), by R&D Systems (2 mentions) Erythropoietin, by Amgen (2 mentions) Recombinant human insulin, by Merck Group (2 mentions) Heparin, by Merck Group (2 mentions) Doxycycline, by Merck Group (2 mentions) Human holo transferrin, by Merck Group (2 mentions) L glutamine, by Thermo Fisher Scientific (2 mentions) Fetal calf serum (fcs), by Thermo Fisher Scientific (1 mentions) Dmem glutamax media, by Thermo Fisher Scientific (1 mentions) Non essential amino acids (neaa), by Thermo Fisher Scientific (1 mentions) Antibiotic antimycotic solution, by Merck Group (1 mentions) Interleukin 6 (il 6), by R&D Systems (1 mentions) Il 10, by R&D Systems (1 mentions)

7 protocols using human stem cell factor

1

Isolation and Culture of Human Lung Mast Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nonlesional tissue from lung resections was obtained after surgery. Tissue was enzymatically digested by methods adapted from (Sanmugalingam et al. 2000; Cruse et al. 2005) and mast cells were isolated, using the Dynal® magnetic bead system using CD117 antibody‐coated beads (Miltenyi Biotech), as described by Okayama et al. (1994). Human Lung Mast Cell (HLMCs) were cultured in DMEM+Glutamax media (Gibco) containing 1% antibiotic–antimycotic solution (Sigma), 1% non‐essential amino acids, 10% fetal calf serum (Gibco) and supplemented with 100 ng/mL human stem cell factor, 50 ng/mL IL‐6 and 10 ng/mL IL‐10 (R&D systems). For histamine assays mast cells were isolated from human lung tissue by a method described by Lewis et al. (2013) and used within 24 h.
Wajdner H.E., Farrington J., Barnard C., Peachell P.T., Schnackenberg C.G., Marino JP J.r., Xu X., Affleck K., Begg M, & Seward E.P. (2017). Orai and TRPC channel characterization in FcεRI‐mediated calcium signaling and mediator secretion in human mast cells. Physiological Reports, 5(5), e13166.
+ Open protocol
+ Expand
2

Isolation and Culture of Ph+ B-ALL Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Heparinized bone marrow samples were collected from 6 patients with newly diagnosed Ph+ B-ALL (detailed information for these patients are provided in Supplementary Table S2). Mononuclear cells (MNCs) were then separated by density gradient centrifugation using Lymphoprep reagent (Stemcell Technologies). Subsequently, MNCs were cultured in StemSpan basic media (Stemcell Technologies) supplemented with 10 ng/mL human stem cell factor, 10 ng/mL human IL-3, 10 ng/mL human IL-6 (all above cytokines were purchased from R&D Systems), 100 U/mL penicillin, and 100 μg/mL streptomycin (both from BBI Life Sciences). This study was approved by the Institutional Review Board of the Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Informed consent for the in vitro drug testing studies was obtained in accordance with the Declaration of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine.
Xiao X., Liu P., Li D., Xia Z., Wang P., Zhang X., Liu M., Liao L., Jiao B, & Ren R. (2020). Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. Journal of Hematology & Oncology, 13, 80.
+ Open protocol
+ Expand
3

Differentiation of Human ES Cells into Hematopoietic Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The differentiation of human ES cells into haematopoietic cells was performed as described previously30 (link). In brief, small clumps of human ES cells were transferred onto mitomycin C-treated C3H10T1/2 cells and co-cultured in haematopoietic cell differentiation medium supplemented with 20 ng/mL human vascular endothelial growth factor (R&D Systems, Minneapolis, MN, USA), which was replaced every 3 days. On day 14 of culture, the haematopoietic progenitor cells (HPCs) within the ES-sacs were collected and then transferred onto fresh mitomycin C-treated C3H10T1/2 cells and further cultivated in differentiation medium supplemented with human thrombopoietin (R&D systems) and combinations of other cytokines/mediators (human stem cell factor (R&D systems), heparin sodium (Ajinomoto Pharmaceuticals Co, Tokyo, Japan), and human erythropoietin (Prospec-Tany TechnoGene, East Brunswick, NJ, USA)). On day 17, an equal volume of the medium was added, and cells were further incubated for 3 days.
Kazuki Y., Yakura Y., Abe S., Osaki M., Kajitani N., Kazuki K., Takehara S., Honma K., Suemori H., Yamazaki S., Sakuma T., Toki T., Shimizu R., Nakauchi H., Yamamoto T, & Oshimura M. (2014). Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies. Scientific Reports, 4, 6136.
+ Open protocol
+ Expand
4

Isolation and Culture of AML Mononuclear Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bone marrow (BM) samples were collected from patients with AML (patient details are provided in Supplementary Table S1). Mononuclear cells were separated with Lymphoprep reagent (Stemcell Technologies) using density gradient centrifugation. They were subsequently cultured in StemSpan SFEM medium (Stemcell Technologies) supplemented with 10 ng/mL human stem cell factor, 10 ng/mL human IL3, 10 ng/mL human IL6 (all cytokines were purchased from R&D Systems), 100 U/mL penicillin, and 100 μg/mL streptomycin (both from BBI Life Sciences).
Written informed consents were obtained from all patients in accordance with the Declaration of Helsinki, and all manipulations were approved by the Institutional Review Board of Guangzhou First People's Hospital, School of Medicine, South China University of Technology (Guangzhou, P.R. China).
Wang P., Zhang Y., Xiang R., Yang J., Xu Y., Deng T., Zhou W., Wang C., Xiao X, & Wang S. (2024). Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib. Cancer Research, 84(6), 905-918.
+ Open protocol
+ Expand
5

Erythroblast Expansion from Cord and Adult Blood

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Newborn cord blood and adult peripheral blood of healthy donors or sickle cell patients were 1:1 diluted with 0.6% ACD(A)-PBS, then MNCs were isolated via Ficoll-Paque premium (GE Healthcare Life Sciences, Uppsala, Sweden) as we previously published.10 (link) The MNCs in the interphase layer were harvested and frozen in liquid nitrogen. The thawed MNCs (4 × 106 per mL) were cultured in a serum-free expansion medium (SFEM, STEMCELL Technologies, Vancouver, BC, Canada) supplemented with erythropoietin (EPO; 3 U/mL; R&D Systems, Minneapolis, MN, USA), human stem cell factor (SCF; 100 ng/mL; R&D Systems), dexamethasone (DEX; 1 μmol/L; Sigma-Aldrich, St. Louis, MO, USA), interleukin (IL)-3 (10 ng/mL; PeproTech, Rocky Hill, NJ, USA), and insulin-like growth factor (IGF)-1 (40 ng/mL, Peprotech) as previously described.10 (link),11 (link) This culture is termed “erythroblast expansion medium.” The cell number of wells that reached 70% confluence was counted, and fresh medium was added to obtain a final concentration at 3–5 × 105 cells/mL. Total cell counts and cell viability were assessed with the trypan blue exclusion method.
Liu S., Wu M., Lancelot M., Deng J., Gao Y., Roback J.D., Chen T, & Cheng L. (2021). BMI1 enables extensive expansion of functional erythroblasts from human peripheral blood mononuclear cells. Molecular Therapy, 29(5), 1918-1932.
+ Open protocol
+ Expand
6

Expansion and Differentiation of HUDEP-2 Cells

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
HUDEP-2 cells were used as previously described3 (link),31 (link), which tested negative for mycoplasma contamination. HUDEP-2 cells were expanded in SFEM (Stem Cell Technologies) supplemented with 100 ng/mL stem cell factor (R&D), 3 UI/mL erythropoietin (Amgen), 10−6 M dexamethasone (Sigma), 1 µ/mL of doxycycline (Sigma), and 2% penicillin-streptomycin (Thermo Fisher). HUDEP-2 cells were differentiated in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 330 µg/mL holo-human transferrin (Sigma), 10 µg/mL recombinant human insulin (Sigma), 2 IU/mL heparin (Sigma), 5% human solvent detergent pooled plasma AB (Rhode Island Blood Center), 3 IU/mL erythropoietin (Amgen), 100 ng/mL human stem cell factor (SCF) (R&D), 1 µg/mL doxycycline (Sigma), 1% L-glutamine (Life Technologies), and 2% penicillin/streptomycin (Life Technologies).
Canver M.C., Lessard S., Pinello L., Wu Y., Ilboudo Y., Stern E.N., Needleman A.J., Galactéros F., Brugnara C., Kutlar A., McKenzie C., Reid M., Chen D.D., Das P.P., Cole M., Zeng J., Kurita R., Nakamura Y., Yuan G.C., Lettre G., Bauer D.E, & Orkin S.H. (2017). Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nature genetics, 49(4), 625-634.
+ Open protocol
+ Expand
7

Expansion and Differentiation of HUDEP-2 Cells

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
HUDEP-2 cells were used as previously described3 (link),31 (link), which tested negative for mycoplasma contamination. HUDEP-2 cells were expanded in SFEM (Stem Cell Technologies) supplemented with 100 ng/mL stem cell factor (R&D), 3 UI/mL erythropoietin (Amgen), 10−6 M dexamethasone (Sigma), 1 µ/mL of doxycycline (Sigma), and 2% penicillin-streptomycin (Thermo Fisher). HUDEP-2 cells were differentiated in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 330 µg/mL holo-human transferrin (Sigma), 10 µg/mL recombinant human insulin (Sigma), 2 IU/mL heparin (Sigma), 5% human solvent detergent pooled plasma AB (Rhode Island Blood Center), 3 IU/mL erythropoietin (Amgen), 100 ng/mL human stem cell factor (SCF) (R&D), 1 µg/mL doxycycline (Sigma), 1% L-glutamine (Life Technologies), and 2% penicillin/streptomycin (Life Technologies).
Canver M.C., Lessard S., Pinello L., Wu Y., Ilboudo Y., Stern E.N., Needleman A.J., Galactéros F., Brugnara C., Kutlar A., McKenzie C., Reid M., Chen D.D., Das P.P., Cole M., Zeng J., Kurita R., Nakamura Y., Yuan G.C., Lettre G., Bauer D.E, & Orkin S.H. (2017). Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nature genetics, 49(4), 625-634.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!